Hypothesis

We propose that age‑related mitochondrial dysfunction in vascular smooth muscle cells (VSMCs) elevates reactive oxygen species (ROS), which activates tissue transglutaminase (TG2) and simultaneously inhibits lysyl oxidase (LOX) activity. Active TG2 cross‑links extracellular proteins, promoting VSMC osteogenic transition, while LOX inhibition prevents tropoelastin cross‑linking, causing its accumulation. The uncross‑linked tropoelastin then binds calcium ions via its exposed carboxyl groups, nucleating hydroxyapatite deposits. This cascade explains the active contribution of VSMC tone and NO signaling to arterial stiffness and links regional differences in NO bioavailability to the higher calcification burden in the abdominal aorta.

Mechanistic Reasoning

• Mitochondrial ROS rise with age and can modulate TG2 activity in other cell types ([5]).
• TG2 activation drives VSMC phenotypic switching toward an osteogenic lineage ([4]).
• ROS also nitrosylate and inhibit LOX, the enzyme that oxidizes lysine residues in tropoelastin for cross‑link formation, leading to accumulation of soluble tropoelastin ([2]).
• Non‑cross‑linked tropoelastin presents multiple free carboxyl groups that chelate calcium, facilitating mineral nucleation ([3]).
• Reduced NO bioavailability in the abdominal aorta exacerbates mitochondrial ROS production, creating a regional feed‑forward loop ([1], [6], [7]).

Testable Predictions

• Prediction 1: In human aortic tissue, mitochondrial ROS levels will positively correlate with TG2 activity and inversely correlate with LOX activity across age groups.
• Prediction 2: Segments with higher mitochondrial ROS/TG2 ratio will show greater accumulation of uncross‑linked tropoelastin and increased calcium deposits, independent of collagen content.
• Prediction 3: Pharmacological scavenging of mitochondrial ROS (e.g., with MitoQ) in ex‑vivo cultured aortic rings will decrease TG2 activation, restore LOX‑mediated tropoelastin cross‑linking, and reduce calcium uptake.
• Prediction 4: Abdominal aortic samples will exhibit higher mitochondrial ROS, TG2 activity, and lower LOX activity than thoracic counterparts, matching their higher stiffness and calcification scores.

Experimental Approach

• Obtain paired thoracic and abdominal aortic segments from organ donors (age stratified 30‑80 y).
• Measure mitochondrial ROS (MitoSOX fluorescence), TG2 activity (fluorogenic substrate assay), LOX activity (Amplex Red‑based assay), and quantify soluble vs cross‑linked tropoelastin (Western blot under reducing/non‑reducing conditions).
• Assess calcium deposition via Alizarin Red staining and von Kossa staining, and determine osteogenic VSMC markers (Runx2, OPN) by immunohistochemistry.
• Perform ex‑vivo treatment with MitoQ or a TG2 inhibitor and repeat measurements to assess causality.
• Statistical analysis: linear mixed models with donor as random effect, segment type and age as fixed effects.

Falsifiability

• If mitochondrial ROS does not correlate with TG2 activation or LOX inhibition, or if ROS scavenging fails to alter tropoelastin cross‑linking and calcification, the hypothesis would be refuted.
• Likewise, if abdominal and thoracic segments show no regional differences in the ROS‑TG2‑LOX axis despite disparate stiffness and calcification, the proposed regional mechanism would be invalidated.